Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $58.8 million.

  • Regenxbio's Cash & Equivalents rose 385.93% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year increase of 385.93%. This contributed to the annual value of $57.5 million for FY2024, which is 6663.58% up from last year.
  • Latest data reveals that Regenxbio reported Cash & Equivalents of $58.8 million as of Q3 2025, which was up 385.93% from $79.6 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Cash & Equivalents registered a high of $345.2 million during Q4 2021, and its lowest value of $34.5 million during Q4 2023.
  • Its 5-year average for Cash & Equivalents is $127.9 million, with a median of $97.0 million in 2022.
  • Per our database at Business Quant, Regenxbio's Cash & Equivalents surged by 31993.63% in 2021 and then crashed by 7191.5% in 2022.
  • Quarter analysis of 5 years shows Regenxbio's Cash & Equivalents stood at $345.2 million in 2021, then tumbled by 71.91% to $97.0 million in 2022, then crashed by 64.39% to $34.5 million in 2023, then skyrocketed by 66.64% to $57.5 million in 2024, then grew by 2.22% to $58.8 million in 2025.
  • Its last three reported values are $58.8 million in Q3 2025, $79.6 million for Q2 2025, and $130.1 million during Q1 2025.